Previous 10 | Next 10 |
As one of the largest pharma companies out there, I suppose it stands to reason that Roche ( OTCQX:RHHBY ) would have an above-average level of newsflow, but tracking the developments at Roche over the last couple of months has been like trying to sip from a firehose. It’s well worth ...
Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha , iTunes , Stitcher and Spotify . The crisis at Boeing is deepening after the planemaker halted production of a 737 line for the first time in two decades, as the ...
Merger activity decreased with four new deals announced and two deals closing. Deal Statistics: New Deals: The acquisition of Diplomat Pharmacy (DPLO) by OptumRx for $300 million or $4.00 per share in cash. The acquisition of Synthorx (THOR) by Sanofi (SNY) for $2.35 billio...
The FTC closes its probe into Roche's ( OTCQX:RHHBY ) $4.8B acquisition of Spark Therapeutics (NASDAQ: ONCE ). More news on: Roche Holding AG, Spark Therapeutics, Inc., Healthcare stocks news, Top stock market news Read more ...
After big biopharma Astellas (OTC: ALPMY) (OTC: ALPMF) agreed to acquire clinical-stage gene therapy company Audentes Therapeutics (NASDAQ: BOLD) for $3 billion in cash, uniQure 's (NASDAQ: QURE) shares have jumped 13% at 12:15 pm EDT on Tuesday. Although Audentes and uni...
Introduction I have covered companies developing immunotherapy treatments, with a focus on T cell therapies. While I have no doubt T cell therapies will be the next pillar in cancer treatments, current generation of therapies are plagued with various limitations. For example, approved CA...
This article is part of a series that provides an ongoing analysis of the changes made to John Paulson’s 13F stock portfolio on a quarterly basis. It is based on Paulson’s regulatory 13F Form filed on 11/14/2019. Please visit our Tracking John Paulson’s Paulson & Co...
Merger activity decreased, with three new deals announced and five deals closing. Deal Statistics: New Deals: The acquisition of Carolina Financial Corporation (CARO) by United Bankshares (UBSI) for $1.1 billion in an all-stock deal. Under the terms of the agreement, United will...
This article is part of a series that provides an ongoing analysis of the changes made to Prem Watsa's 13F portfolio on a quarterly basis. It is based on Watsa's regulatory 13F Form filed on 11/14/2019. Please visit our Tracking Prem Watsa's Fairfax Financial Holdings Portfolio series to g...
Four times a year, I spend several hours combing through Form 13F filings from the hedge funds that specialize in M&A. I document and analyze which merger stocks the funds have bought and which ones they haven't. I then compile the top 10 stocks held in these funds and share it with everyo...
News, Short Squeeze, Breakout and More Instantly...
Spark Therapeutics Inc. Company Name:
ONCE Stock Symbol:
NASDAQ Market:
Spark Therapeutics Inc. Website:
Genetics is the study of genes, their variations and hereditary characteristics. As Live Science describes it , genetics involves looking at how traits are passed on through generations. So, what is genetics investing? When it comes to genetics investing, companies in this niche...
After big biopharma Astellas (OTC: ALPMY) (OTC: ALPMF) agreed to acquire clinical-stage gene therapy company Audentes Therapeutics (NASDAQ: BOLD) for $3 billion in cash, uniQure 's (NASDAQ: QURE) shares have jumped 13% at 12:15 pm EDT on Tuesday. Although Audentes and uni...
PHILADELPHIA, Oct. 25, 2019 (GLOBE NEWSWIRE) -- Spark Therapeutics (NASDAQ:ONCE), a fully integrated, commercial gene therapy company dedicated to challenging the inevitability of genetic disease, today announced that the Galien Foundation has awarded the prestigious 2019 Prix Galien USA Aw...